Thu, November 19, 2009
Wed, November 18, 2009
Tue, November 17, 2009
Mon, November 16, 2009
Sun, November 15, 2009
Fri, November 13, 2009
Thu, November 12, 2009
Wed, November 11, 2009
Tue, November 10, 2009
Mon, November 9, 2009
Fri, November 6, 2009
Thu, November 5, 2009
Wed, November 4, 2009
Tue, November 3, 2009
Mon, November 2, 2009
Sun, November 1, 2009
Fri, October 30, 2009
Thu, October 29, 2009
Wed, October 28, 2009
Tue, October 27, 2009
Mon, October 26, 2009
Sun, October 25, 2009
Fri, October 23, 2009
Thu, October 22, 2009
Wed, October 21, 2009
Tue, October 20, 2009
Mon, October 19, 2009
Fri, October 16, 2009
Thu, October 15, 2009
Wed, October 14, 2009
Tue, October 13, 2009
Mon, October 12, 2009
Fri, October 9, 2009

Cypress Bioscience, Inc. to Present at Oppenheimer 20th Annual Healthcare Conference


  Copy link into your clipboard //health-fitness.news-articles.net/content/2009/ .. penheimer-20th-annual-healthcare-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

SAN DIEGO, CA--(Marketwire - October 30, 2009) - Cypress Bioscience, Inc. (NASDAQ: [ CYPB ]) today announced that Sabrina Martucci Johnson, its Chief Operating Officer and Chief Financial Officer, will present at the Oppenheimer 20th Annual Healthcare Conference on November 3, 2009.

The Oppenheimer conference is being held at the Waldorf=Astoria Hotel in New York, NY. Ms. Johnson is scheduled to present on Tuesday, November 3rd at 1:00 p.m. Eastern Time. The audio broadcast of this presentation can be accessed at [ http://www.veracast.com/webcasts/opco/healthcare09/85108244.cfm ].

A replay of the presentation will be available at the same web address as well as on Cypress' website, [ http://www.cypressbio.com/events.php ].

About Cypress Bioscience

Cypress Bioscience, Inc. provides therapeutics and personalized medicine services, facilitating improved and individualized patient care. Cypress addresses the evolving needs of specialist physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders such as fibromyalgia and rheumatoid arthritis. This approach to improving patient care creates a unique partnership with physicians. Current products include Savella® (milnacipran HCI) and the Avise PG(SM) and Avise MCV(SM) therapeutic monitoring, diagnostic and prognostic tests for rheumatoid arthritis.

For more information about Cypress, please visit the Company's website at [ www.cypressbio.com ].


Publication Contributing Sources